Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)

Summary

To evaluate the efficacy of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy.

Timeline

Start

2019-11-12

Primary completion

2022-02-23

Completion

2022-02-23

Outcome

Missed primary endpoint

registry MEAN NYX-2925: -2.01 (Standard Deviation 1.821) units on a scale MEAN Placebo: -2.27 (Standard Deviation 2.102) units on a scale NCT04146896 ↗

registry analysis (superiority test); NYX-2925 vs Placebo; p = 0.704; t-test, 2 sided NCT04146896 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NYX-2925	Small molecule	50 mg	Oral

Indications